CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
杀伤细胞耗竭：向 NK 细胞样表型转变是 CAR-T 细胞耗竭的标志
英文原题：Killer fatigue: Transition to NK-cell-like phenotype is a signature of CAR-T cell exhaustion.
查看英文原题
Killer fatigue: Transition to NK-cell-like phenotype is a signature of CAR-T cell exhaustion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞的耗竭会阻碍其治疗效果，尤其是在治疗实体瘤时。在本期 Cell 中，Good 等人建立了一种抗原驱动的 CAR-T 细胞耗竭体外模型，用以表征功能障碍的特征，包括向自然杀伤（NK）样表型的转变，并提出新的基因靶点以防止耗竭。
展开英文摘要原文
Exhaustion of chimeric antigen receptor (CAR)-T cells hinders their therapeutic efficacy, especially in treating solid tumors. In this issue of Cell, Good et al. develop an in vitro model of antigen-driven CAR-T cell exhaustion to characterize signatures of dysfunction, including a transition to a natural killer (NK)-like phenotype, and suggest new gene targets to prevent exhaustion.
论文信息
- 作者
- Hong M、Chen YY
- 第一作者单位
- Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.United States
- 通讯作者单位
- Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, CA 90095, USA. Electronic address: yvonne.chen@ucla.edu.United States
- 文献类型
- 评论
- 期刊
- Cell2021 Dec 9
- 原文标识
- PubMed 34890549 · DOI 10.1016/j.cell.2021.11.015